Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Coker

Showing results (181-190 of 187) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 187 results.
JCI Insight|May 5, 2026
Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastomaJesse A Coker, Steven R Martinez, Sang Hoon Han, et al.
Molecular Systems Biology|July 7, 2020
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screensEmanuel Gonçalves, Aldo Segura-Cabrera, Clare Pacini, et al.
Nature Communications|November 14, 2025
The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programsTreg Grubb, Pooneh Koochaki, Sayed Matar, et al.
Nature|February 24, 2022
Effective drug combinations in breast, colon and pancreatic cancer cellsPatricia Jaaks, Elizabeth A Coker, Daniel J Vis, et al.
Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.
Cancer Discovery|March 8, 2024
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug CombinationsAzadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Pageof 19

Showing results (181-190 of 187) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 187 results.
JCI Insight|May 5, 2026
Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastomaJesse A Coker, Steven R Martinez, Sang Hoon Han, et al.
Molecular Systems Biology|July 7, 2020
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screensEmanuel Gonçalves, Aldo Segura-Cabrera, Clare Pacini, et al.
Nature Communications|November 14, 2025
The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programsTreg Grubb, Pooneh Koochaki, Sayed Matar, et al.
Nature|February 24, 2022
Effective drug combinations in breast, colon and pancreatic cancer cellsPatricia Jaaks, Elizabeth A Coker, Daniel J Vis, et al.
Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.
Cancer Discovery|March 8, 2024
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug CombinationsAzadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Pageof 19